Prevalence and type of first amyloid extracardiac symptoms and cardiac disorders history and time from their occurrence to diagnosis between Al and transthyretin cardiac amyloidosis - 09/01/21

Doi : 10.1016/j.acvdsp.2020.10.097

M. Kharoubi ^1,^2,^⁎ , M. Bézard ^1,², A. Galat ^1,², F. Le Bras ^1,³, E. Poullot ^1,⁴, L. Hittinger ^1,², V. Moulinier Frenkel ^1,⁵, P. Fanen ⁶, B. Funalot ^1,⁶, A. Moktefi ^1,⁴, J.P. Le Faucheur ^7,⁸, A. Mukedaisi ⁹, J. Deux ^1,¹⁰, T. Gendre ⁸, V. Audard ^1,¹¹, E. Audureau ^1,¹², E. Bequignon ¹³, V. Plante ^1,⁸, S. Oghina ^1,², T. Damy ^1,²
¹ French Referral Centre for Cardiac Amyloidosis, Cardiogen Network, AP–HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor university hospital, 51, avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
² DHU A-TVB, AP–HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor university hospital, 51, avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
³ Lymphoid Hemopathies Unit, AP–HP (Assistance Publique-Hôpitaux de Paris, Henri Mondor, Créteil 94000, France
⁴ Pathology Department, AP–HP (Assistance Publique-HôpitauxHenri Mondor university hospital, 51, avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
⁵ Immunobiology Department, AP–HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor university hospital, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
⁶ Genetics Department, AP–HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor university hospital, Genetics Department, 51, Avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
⁷ Univ Paris Est Créteil, EA4391, ENT, 8, rue du General Sarrail, 94010 Créteil, France
⁸ Clinical Neurophysiology Unit, AP–HP (Assistance Publique-Hôpitaux de Paris), Henri-Mondor university hospital, Créteil, France
⁹ Nuclear Medicine Department, AP–HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor university hospital, 51, avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
¹⁰ Radiologic Department, AP–HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor university hospital, 51, avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
¹¹ Nephrology and Renal Transplantation Department, AP–HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor university hospital, 51, avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
¹² Public Health Departement, AP-HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor university hospital, 51, avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France
¹³ Orhinolaryngologic Department, AP–HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor university hospital, 51, avenue du Marechal de Lattre de Tassigny, 94010 Creteil, France

^⁎Corresponding author.

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

Aims

Cardiac amyloidosis (CA) have a bad prognosis aggravated by diagnostic delay. Cardiologists should be aware that Amyloidosis Extracardiac Disorders (AECD) and cardiac symptoms and history (ACD) may help to improve CA diagnosis and typing. The aim of this study was to compare AECD and ACD history between different CA types and their relationship with survival.

Method and results

AECD and ACD, from 983 CA patients with a mean age±SD of 73±12 years included from June 2008 to May 2019, were studied. 321 were AL, 434 wild type transthyretin (ATTRwt), and the other were hereditary transthyretin (ATTRv; 16 neurologic and 212 cardio or mixed). Median delay between declaration of symptoms/history and diagnosis varied from 45[54–72] months for ATTRv with neuropathy to 72[63–78] months for ATTRwt. Nature of first AECD or ACD depended on amyloidosis type, with heart failure symptoms for AL (26%), neuropathy (45%) for neurologic ATTRv and integumentary symptoms for ATTRv with cardiopathy or mixed and ATTRwt respectively 39%, and 42%. In AL and ATTRwt, the shorter delay between the first history and the diagnosis was associated with a shorter survival rate (Fig. 1).

Conclusion

Extra-cardiac history, such as integumentary symptoms, present early in the development of CA and increase awareness of physicians for these signs may improve diagnosis. The progressive nature of AECD seems indicating a slower progression of the cardiac involvement.

Le texte complet de cet article est disponible en PDF.

Plan

Disclosure of interest

Export

Vol 13 - N° 1

P. 30 - janvier 2021 Retour au numéro

Article précédent

Prevalence and prognostic value of small fiber neuropathy assessed by Sudoscan ® in transthyretin wild-type cardiac amyloidosis
M. Kharoubi, F. Roche, M. Bézard, D. Hupin, S. Silva, S. Oghina, C. Chalard, A. Zaroui, A. Galat, S. Guendouz, F. Canoui Poitrine, V. Planté-Bordeneuve, L. Hittinger, E. Teiger, J.P. Le Faucheur, T. Damy

| Article suivant

New oral anticoagulants versus vitamine K antagonists among patients with cardiac amyloidosis: effectiveness and safety
E. Cariou, K. Sanchis, M. Galinier, D. Carrie, O. Lairez

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Prevalence and type of first amyloid extracardiac symptoms and cardiac disorders history and time from their occurrence to diagnosis between Al and transthyretin cardiac amyloidosis - 09/01/21

Résumé

Aims

Method and results

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL